Vivos Therapeutics (VVOS) investor relations material

Company overview and business model

• Operates as a medical technology and healthcare services company offering proprietary oral appliances and treatments for obstructive sleep apnea (OSA) and related disorders, with a focus on non-surgical solutions.

• Business model has shifted from dentist-focused training and product sales to a medical-provider focused approach, including acquisitions and alliances with sleep centers and the establishment of Dental and Medical Service Organizations (DSOs/MSOs).

• Recent acquisitions, such as The Sleep Center of Nevada (SCN), and new management models aim to capture both diagnostic and treatment revenues, with expansion plans for additional centers and collaborations.

• The Vivos Method, featuring patented C.A.R.E. appliances, is positioned as a differentiated, non-invasive treatment with limited treatment duration and durable effects.

Financial performance and metrics

• SCN integration in 2025 generated $4.8 million in diagnostic revenue and $2.0 million in treatment revenue for that year.

• Each Sleep Optimization (SO) team at SCN locations is projected to generate over $500,000 per month in collections with contribution margins above 50%.

• Revenue streams include diagnostic and treatment services, recurring appliance sales, SleepImage HST leasing, training, billing services, and telemedicine-based therapies.

Use of proceeds and capital allocation

• No proceeds will be received from the resale of shares by the selling stockholder; proceeds may be received only if warrants are exercised for cash.

• Any proceeds from warrant exercises (up to $8.29 million if fully exercised) will be used for general corporate purposes, including working capital.